MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Magnetic Nanoparticles for Tissue-Specific Drug Delivery

University of Nebraska Medical Center / UNeMed Corporation
Site-specific localization and highly efficient drug delivery.

Full description

Summary
One of the limitations in the drug delivery field is the inability to
specifically target therapeutic or imaging agents to certain tissues,
organs or tumors. Magnetic nanoparticles have emerged as
effective drug delivery systems, which can be directed by externally
applied magnetic fields and specifically tailoring their functional
properties. Unfortunately, available magnetic nanoparticles with
therapeutic and imaging agents have several limitations: creation
involves a complex multi-step process, they have a limited agent
loading capacity, experience rapid bound agent dissociation, and
go through rapid loss of magnetization ability. Researchers at the
University of Nebraska Medical Center have developed a novel
magnetic nanoparticle technology with a high drug-loading
capacity, adjustable release profile, high aqueous dispersion
stability, biocompatibility with tissue and cells, and prolonged
stable retention of magnetic properties.


Market Value
This technology can be used to increase the efficacy, lower toxicity,
and eliminating side effects of existing and novel therapeutical
agents. An alternative market is the medical imaging sector, which
will be able to achieve more precise and rapid methods for
imaging diseases and conditions. The main competitive
advantages of the novel magnetic nanoparticles include simple
and inexpensive production, ability to effectively incorporate and
release in controlled manner wide variety of therapeutical or
imaging agents, and stable magnetic properties of complexed
nanoparticles.


Features and Benefits
• Effective drug delivery system
• Specifically target tumors and other pathological conditions
• High drug loading capacity
• A desirable release profile


Patent information

Application Published US-2007-0264199-A1

(TID - 59)

Type of business relationship sought

UNeMed Corporation offers a variety of licensing options and collaborative development opportunities with the University of Nebraska Medical Center.

Licensing contact

Toni Harris
Marketing Specialist

Contact directly

Company details

University of Nebraska Medical Center / UNeMed Corporation

Technology Marketing and Licensing for The University of Nebraska Medical Center

View profile

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us